Medpace (NASDAQ:MEDP) Stock Rating Lowered by Zacks Research

Medpace (NASDAQ:MEDP) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

A number of other brokerages also recently issued reports on MEDP. TD Cowen lifted their price target on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. Truist Financial set a $555.00 price target on shares of Medpace in a research note on Monday, October 27th. Mizuho set a $660.00 price objective on shares of Medpace in a research report on Friday. Finally, Cowen reaffirmed a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $491.27.

Medpace Price Performance

Shares of MEDP stock traded up $2.01 on Monday, hitting $610.44. The stock had a trading volume of 49,758 shares, compared to its average volume of 196,008. The firm has a market capitalization of $17.20 billion, a P/E ratio of 42.69, a P/E/G ratio of 2.01 and a beta of 1.43. The company’s 50 day moving average price is $581.43 and its 200-day moving average price is $506.43. Medpace has a 1 year low of $250.05 and a 1 year high of $626.26.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts forecast that Medpace will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares of the company’s stock, valued at approximately $381,694,426.96. This trade represents a 0.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 387,925 shares of company stock worth $233,386,647. Company insiders own 20.30% of the company’s stock.

Hedge Funds Weigh In On Medpace

Large investors have recently bought and sold shares of the company. Quent Capital LLC purchased a new position in Medpace during the third quarter worth about $25,000. Optiver Holding B.V. acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $27,000. Geneos Wealth Management Inc. boosted its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Quarry LP acquired a new position in Medpace during the third quarter worth $35,000. Finally, Employees Retirement System of Texas purchased a new position in Medpace in the second quarter worth $36,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.